Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant diffuse glioma. Branded Modeyso, the ...

Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018.

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

The U.S. Centers for Medicare & Medicaid Services adopted several significant policy changes in the Medicare inpatient final ...

Casi Pharmaceuticals Inc. announced the U.S. FDA has cleared its IND application for CID-103, a monoclonal antibody targeting ...

Novartis AG’s financial update included good news about Scemblix (asciminib), a third-generation allosteric tyrosine kinase ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), ...

The U.S. FDA has approved Innovent Biologics, Inc.’s IND application to initiate a phase I clinical trial of its oral GLP-1R ...

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) were trading at $393.83, down $78.44, or 16%, on top-line results from the phase II dose-ranging study evaluating the safety and efficacy of its ...

Deep learning tools for protein design can also be used to create molecules that bind to them. Certain peptides, such as ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...